Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries

Introduction The impact of respiratory syncytial virus (RSV) is increasingly being recognized in older adults, however economic burden data is sparse. This study describes the burden of RSV and associated direct and indirect costs in adults aged 60 + years in real-world clinical practice across five European countries. Methods Data were drawn from the Adelphi RSV Disease Specific Program (DSP™), a cross-sectional survey of physicians and patients in France, Germany, Italy, Spain, and the United Kingdom conducted December 2023–June 2024. Patients aged 60 + with a confirmed RSV diagnosis were included. Physicians provided data on resource use and supportive care needs, and patients on paid and unpaid productivity loss. Country-specific unit costs were used to calculate direct and indirect costs. Patients were stratified by symptom duration from onset (acute- [A-]RSV: